Safety And Efficacy Of Bosutinib

CompletedOBSERVATIONAL
Enrollment

702

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Bosutinib

The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.

Trial Locations (1)

151-8589

Shibuya-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY